Guess which ASX All Ords share is surging 16% after announcing a new finance chief

Is this announcement the real reason for the rise?

| More on:
a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Race Oncology Ltd (ASX: RAC) shares are on form and racing higher on Monday.

In afternoon trade, the ASX All Ords share is up over 16% to $1.81.

This means that the oncology company's shares are now up an impressive 130% since this time last month.

Why is this ASX All Ords share surging on Monday?

Investors have been buying the company's shares today following the announcement of the appointment of its new chief financial officer (CFO).

According to the release, the company has named Brendan Brown as its new CFO, effective from Monday 1 April 2024, succeeding Ms Christina Manfre.

The release notes that Brown is a partner and director of Prime Accounting & Business Advisory, which is part of the Prime Financial Group (ASX: PFG).

Race Oncology highlights that he brings significant practical experience to the company, having worked with numerous life science clients through the past 20 years. In addition, Brown is a chartered accountant, and registered tax agent with a Bachelor of Commerce in Accounting from La Trobe University.

The company's CEO, Dr Daniel Tillett, was pleased with the appointment. He commented:

We thank Christina for her time with Race and welcome Brendan to his new role as Race CFO. Race has had a productive working relationship with Prime over the last two years being responsible for Race's successful R&D Tax Incentive claims. We are pleased to be expanding our engagement with both Brendan and Prime as we advance our new formulation of bisantrene in the clinic in 2024.

Why such a jump?

While I'm sure the appointment has gone down well with shareholders, it's unlikely to be the real reason for the ASX All Ords share's strong rise today.

As I mentioned at the top, Race Oncology's shares have been on fire this month. This has been driven by excitement around the potential of its bisantrene product.

Earlier this month, the ASX All Ords share revealed that bisantrene has shown potent activity in a range of patient-derived primary acute myeloid leukemia (AML) cells and in mouse models of AML.

The combination of bisantrene and decitabine was found to exhibit robust anticancer synergy in both cell and mouse AML models. In addition, key cellular pathways targeted by bisantrene were identified, further supporting the use of bisantrene in combination with decitabine as a low intensity treatment for AML patients.

Overall, management believes preclinical data is "highly supportive of clinical trials of the new bisantrene formulation (RC220) combined with oral decitabine, as a low intensity treatment approach, for AML patients."

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Prime Financial Group. The Motley Fool Australia has recommended Prime Financial Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

Guess which ASX 300 healthcare stock is storming higher on Chinese patent news

Here's why this healthcare share is catching the eye on Thursday.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

Guess which ASX healthcare stock is rocketing 110% on US product launch

Shareholders of this stock are smiling on Wednesday. Why is it rocketing?

Read more »

Man holding out Australian dollar notes, symbolising dividends.
Healthcare Shares

Own CSL shares? You're receiving a healthy dividend boost today!

The bank accounts of CSL shareholders are about to receive a healthy payment.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

Blast off! Mesoblast share price surging 60%

Mesoblast shares are skyrocketing today.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

CSL share price lower despite US FDA boost

The regulator has approved a treatment for sufferers of chronic kidney disease.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »